Maintenance Lurbinectedin + Atezolizumab Improves Survival Outcomes in ES-SCLC in IMforte Trial

First Look With ASCO Daily News presents Dr. Luis Paz-Ares of Hospital Universitario 12 de Octubre on the results of the phase 3 IMforte trial of lurbinectedin plus atezolizumab as first-line maintenance treatment for patients with extensive-stage small cell lung cancer. Read the full abstract (Abstract 8006) from the 2025 ASCO Annual Meeting: https://meetings.asco.org/abstracts-presentations/243670 For more on ASCO25, visit https://dailynews.ascopubs.org/meetings/asco-annual-meeting _Data as of May 5, 2025_

Video Lainnya